Quantcast
Channel: City Air News - Nation
Viewing all articles
Browse latest Browse all 11253

BJP issues note on Drug Pricing Controversy

$
0
0
Author(s): 
New Delhi/Jalandhar, January 12, 2015: Bharatiya Janata Party (BJP), Central Office, in a statement issued today said false propaganda from the opposition has yet again been exposed. Seeing no signs of revival, opposition is now playing politics in the name of poor & the ill.
It further said nor will they once give an account of what did they do for healthcare in the last 10 years, but as election nears they are shamelessly spreading canards in the name of the medicine prices. The party which did not spare specially abled people from its corruption are now blaming us.
“We are a party which wants to eradicate the nation of the disease called Congress. Can we ever think of increasing prices of medicines that cure diseases?”, it said in the  release.
BJP added infact, total number of scheduled drugs whose prices have been fixed, has increased from 440 in May 2014 to 489 as on date.
It said there have been false allegations regarding the prices of specific drugs such as Glivec (generic name Imatinib), which is anti-cancer drug, Cardace ( generic name Remipril), and Plavix(generic name Clopidogrel), which are drugs used in the treatment of cardio vascular diseases, have gone up manifold on account of the withdrawal of the internal guidelines issued earlier by the National Pharmaceutical Pricing Authority (NPPA) under Drug (Price Control) Order, 2013.   These allegations are factually incorrect & far from the truth because the price notifications of anti diabetic & cardio vascular therapies issued by NPPA on July 10, 2014 have not been withdrawn.

Brand Name of drug (Company)

Molecule

Earlier Price as per newspaper (Rs.)

Current Price as per newspaper (Rs.)

Price verified by NPPA from Delhi Market

Remarks

Geftinat

(M/s Natco Pharma)

Geftinib 250mg

5,900

 

11,500

 

Rs. 5,900for 30 tabs,

batch no. 700805, mfg dt- 08/2014, exp. dt.– 07/2016,

 

Non-scheduled medicine

 

No change in price

 

 

Glivec 400mg

 

(M/s Novartis)

 

 

 

 

Imatinib

 

8,500

 

1,08,000

 

Rs. 8452.38for 30 tabs as per Form- V dt. 10.06.2014

 

 

Scheduled medicines under DPCO, 2013,

 

No change in price

 

Cardace 5mg

(M/s Sanofi)

Ramipril

92

 

128

 

 

Rs.92.10for 10 tabs

batch no. 2914016, mfg. dt. 08/2014,exp. dt 07/2017

 

 

Non-scheduled medicine, Actually price has been brought down to Rs. 92.10 /for 10 tab on 10.07.2014 by NPPA from Rs 128 .80 in April 2014

 

 

Plavix 75 mg

(M/s Sanofi)

 

Clopidogrel

147

1,615

Rs. 147.44for 14 tabs, batch no. 4A580, mfg. dt, 03/2014, exp. dt., 02/2017

Scheduled medicine

 

No change in price

 

 

 

Moxicip 400

(M/s Cipla)

Moxifloxacin

250

399

Rs.250.00for 10 tabs, batch no. A41437, mfg dt. 07/2014, exp. dt. 06/2017

 

Non-scheduled medicine

 

No change in price

 

Tarivid 200

(M/s Sanofi)

 

 

Ofloxacin 200 mg

34

173

Rs. 27.20for 5 tabs, batch no. 0214503, mfg. dt., 08/2014, exp. dt., 07/2017

Scheduled medicine

 

No change in price

 

 

Storvas 10 Tab

(M/s Ranbaxy)

Atorvastin  10mg

62

97

Rs.62.06for 10 tabs, batch no. 2593309, mfg. dt- 02/2014, exp. dt- 01/2016

 

Scheduled medicine

 

No change in price

 

BJP further said the prices of drugs are fixed/ revised by the National Pharmaceutical Pricing Authority (NPPA) under Drug (Price Control) Order, 2013. NPPA is an independent body of experts constituted by Government of India.
It added till May 2014, NPPA had fixed ceiling prices of 440 scheduled drugs. Since then, ceiling prices have been fixed for additional 49 scheduled drugs. Thus, total number of scheduled drugs whose prices have been fixed, has in fact increased from 440 to 489 as on date. This is expected to provide financial relief to consumers by more than 70 crore rupees per year.
“In addition, prices of 108 non-scheduled drugs for treatment of cardio vascular and diabetes were fixed by NPPA under para 19 of DPCO on 10.07.2014. The action taken by the NPPA in respect of 108 drug formulations related to anti- diabetic and cardio vascular therapies is expected to provide financial relief to the tune of around Rs.350 crore to the consumers”, said the release. 
(Rajat Kumar/Jalandhar)
-----------------------------
Readers may send their news/views/feedback to us:
cityairnews@gmail.com
-----------------------------
Join us on facebook (fb): www.facebook.com/cityairnews
Read ludhianatribune.com: http://ludhianatribune.com/
Also visit: http://www.punjabcitynews.com/
 
Date: 
Monday, January 12, 2015

Viewing all articles
Browse latest Browse all 11253

Trending Articles